The Problem
Traditional drug discovery takes 10–15 years and $2.6B per approved molecule. Most candidates fail in late-stage clinical trials because early screening optimizes for binding affinity alone, ignoring causal mechanisms of action, off-target effects, and synthesizability constraints.
ACHT + VAP Solution
ACHT's Bayesian optimization explores chemical space 10–100x faster than grid search, while generative models propose novel scaffolds. Causal discovery on STRING v12.0 protein networks identifies mechanistic pathways. VAP's self-falsification catches false-positive binding predictions before they waste wet-lab resources.
See full platform at BioSciences site